The criminal case against John Thomas Howard and his brother Bob Howard of CANARX represents a watershed moment in how federal authorities are pursuing illegal drug importation schemes. But what makes this prosecution particularly noteworthy isn't just the charges—smuggling, conspiracy, and importing misbranded drugs—filed after John Howard's arrest on Nov. 8 in the Detroit-Canada tunnel. It's that the government's case was built substantially on testimony from Gary Becker, the CEO of ScriptSourcing, a competitor operating the same illegal business model. When facing FDA scrutiny, Becker chose to cooperate rather than fight, and his detailed evidence has become the foundation of one of the first criminal cases against the so-called alternative funding programs industry.

The AFP business promises something seductive: cheap medications sourced from international markets for Americans drowning in prescription drug costs. CANARX, based in Windsor, Ontario and established in 2002, marketed this model aggressively. Yet the FDA and Department of Homeland Security have consistently maintained that these operations violate U.S. law, and for good reason. The affidavit filed by FDA special agent Dustin Dobbs on Oct. 29 details two incidents in which ScriptSourcing's imported medications caused serious harm—one patient hospitalized from a bowel obstruction after using misbranded Monjaro, another seriously injured by a counterfeit drug. When drugs bypass regulatory oversight, patients become unwitting test subjects.

Becker's transformation from AFP operator to government witness illuminates how the FDA has dismantled ScriptSourcing's operation. By May 2026, Becker was cooperating fully, providing spreadsheets showing approximately 16,549 prescription drugs dispensed between his company and CANARX from 2021 to 2026. More damaging still were recorded phone calls between June and July 2026 in which John Howard discussed importation routes with Becker, explicitly aware, according to Dobbs' affidavit, that these drugs 'were not allowed to enter into the United States legally.' Among the shipments being prepared were packages containing Neupro, an FDA-regulated drug for Parkinson's disease and restless legs syndrome.

CANARX's legal counsel has insisted the company was operating legally and that the Howard brothers 'deny all the charges against them, will defend vigorously, and expect to be vindicated in court.' Yet the evidence suggests otherwise. Pharmaceutical companies like Gilead Sciences, which filed a civil lawsuit in December 2024 alleging CANARX illegally imported its HIV drug Biktarvy, have welcomed this prosecution as overdue accountability.

The real lesson here transcends any single case. When one company's illegal practices become another's blueprint, and when facing consequences forces a choice between individual survival and collective wrongdoing, the incentives shift. Becker's decision to cooperate over contest may mark the beginning of the end for the AFP model's facade of legitimacy. Sometimes progress against dangerous schemes requires unlikely allies.